ANNOUNCES EXECUTIVE RETIREMENT
TO HOST CONFERENCE CALL AUGUST 3, 2016 AT 11:00 A.M. ET
BATON ROUGE, La., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading home health and hospice company, today reported its financial results for the three and six-month periods ended June 30, 2016.
Three-Month Periods Ended June 30, 2016 and 2015
- Net service revenue increased $46.6 million to $360.7 million compared to $314.1 million in 2015.
- Net income attributable to Amedisys, Inc. of $10.7 million compared to $10.6 million in 2015.
- Net income attributable to Amedisys, Inc. per diluted share remained at $0.32 per diluted share when compared to 2015.
Adjusted Results*
- Adjusted net service revenue of $361.7 million compared to $314.1 million in 2015.
- Adjusted net income attributable to Amedisys, Inc. of $14.1 million compared to $14.5 million in 2015.
- Adjusted net income attributable to Amedisys, Inc. per diluted share of $0.42 compared to $0.43 in 2015.
- Adjusted EBITDA (defined as net income (loss) attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization excluding certain items) of $29.8 million compared to $31.7 million in 2015.
Six-Month Periods Ended June 30, 2016 and 2015
- Net service revenue increased $93.8 million to $709.5 million compared to $615.7 million in 2015.
- Net income attributable to Amedisys, Inc. of $16.9 million compared to $24.4 million net loss in 2015.
- Net income attributable to Amedisys, Inc. per diluted share increased $1.24 to $0.50 compared to $0.74 net loss per diluted share in 2015.
Adjusted Results*
- Adjusted net service revenue of $710.5 million compared to $615.7 million in 2015.
- Adjusted net income attributable to Amedisys, Inc. of $25.0 million compared to $24.3 million in 2015.
- Adjusted net income attributable to Amedisys, Inc. per diluted share of $0.74 compared to $0.73 in 2015.
- Adjusted EBITDA of $53.8 million compared to $58.0 million in 2015.
* See pages 11 and 12 for the reconciliations of non-GAAP financial measures to GAAP measures.
Executive Retirement
On August 2, 2016, Ronald A. LaBorde, the Vice Chairman and Chief Financial Officer of the Company, announced his intention to retire from the Company and the Board of Directors as of January 2, 2017.
Paul B. Kusserow, President and Chief Executive Officer stated, “I am proud of the strong results our team delivered in the second quarter, even as we incurred deeper than anticipated software implementation disruption costs. We delivered strong growth across the board in all segments, drove improving clinical quality metrics and saw reduced employee turnover. We are continuing to progress successfully through our technology transformation and remain confident in our ability to deliver on the efficiencies that we have promised to our shareholders.”
Kusserow continued, “Lastly, while five months away, I would like to thank Ronnie LaBorde for his contribution to Amedisys which been invaluable, particularly during the turnaround in 2014. I appreciate his contribution as a trusted colleague and friend. He will leave the company in a strong and stable position with a great future trajectory. You couldn’t ask for a better legacy.”
We urge caution in considering the current trends disclosed in this press release. The home health and hospice industry is highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com. We disclaim any obligations to update disclosed information on trends.
Earnings Call and Webcast Information
To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through September 3, 2016 by dialing (877) 660-6853 (Toll- Free) or (201) 612-7415 (Toll) and entering conference ID #13641920.
A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.
Amedisys, Inc. (the “Company”) is headquartered in Baton Rouge, Louisiana and our common stock trades on the NASDAQ Global Select Market under the symbol “AMED”.
Additional information
Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. We also use our website to expedite public access to time-critical information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.
Forward-Looking Statements
When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, our ability to comply with requirements stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward- looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
Non-GAAP Financial Measures
This press release includes the following non-GAAP financial measures as defined under SEC rules: (1) EBITDA, defined as net income (loss) attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization; (2) adjusted EBITDA, defined as EBITDA excluding certain items; (3) adjusted net service revenue, defined as net service revenue excluding certain items; (4) adjusted net income attributable to Amedisys, Inc., defined as net income (loss) attributable to Amedisys, Inc. excluding certain items; and (5) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. In accordance with SEC rules, we have provided herein a reconciliation of these non-GAAP financial measures to the most directly comparable measures under GAAP. Management believes that these are useful gauges of our performance and are common measures used in our industry to assess relative financial performance among companies.
AMEDISYS, INC. AND SUBSIDIARIES
SELECT CONSOLIDATED FINANCIAL STATEMENT DATA AND SUPPLEMENTAL INFORMATION
(Amounts in thousands, except share, per share data and statistical information)
| Balance Sheet Information | ||||||
| June 30, 2016 | December 31, 2015 | |||||
| (Unaudited) | ||||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 9,968 | $ | 27,502 | ||
| Patient accounts receivable, net of allowance for doubtful accounts of $15,950 and $16,526 | 152,213 | 125,010 | ||||
| Prepaid expenses | 7,931 | 8,110 | ||||
| Other current assets | 9,407 | 14,641 | ||||
| Total current assets | 179,519 | 175,263 | ||||
| Property and equipment, net of accumulated depreciation of $139,433 and $141,793 | 44,617 | 42,695 | ||||
| Goodwill | 280,349 | 261,663 | ||||
| Intangible assets, net of accumulated amortization of $26,525 and $25,386 | 47,728 | 44,047 | ||||
| Deferred income taxes | 121,014 | 125,245 | ||||
| Other assets, net | 37,875 | 32,802 | ||||
| Total assets | $ | 711,102 | $ | 681,715 | ||
| LIABILITIES AND EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 35,070 | $ | 25,682 | ||
| Payroll and employee benefits | 86,075 | 72,546 | ||||
| Accrued expenses | 63,641 | 71,965 | ||||
| Current portion of long-term obligations | 5,000 | 5,000 | ||||
| Total current liabilities | 189,786 | 175,193 | ||||
| Long-term obligations, less current portion | 89,500 | 91,630 | ||||
| Other long-term obligations | 3,991 | 4,456 | ||||
| Total liabilities | 283,277 | 271,279 | ||||
| Equity: | ||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding | — | — | ||||
| Common stock, $0.001 par value, 60,000,000 shares authorized; 35,136,248 and 34,786,966 shares issued; and 33,499,944 and 33,607,282 shares outstanding | 35 | 35 | ||||
| Additional paid-in capital | 523,583 | 504,290 | ||||
| Treasury stock at cost, 1,636,304 and 1,179,684 shares of common stock | (45,829 | ) | (26,966 | ) | ||
| Accumulated other comprehensive income | 15 | 15 | ||||
| Retained earnings | (50,897 | ) | (67,806 | ) | ||
| Total Amedisys, Inc. stockholders’ equity | 426,907 | 409,568 | ||||
| Noncontrolling interests | 918 | 868 | ||||
| Total equity | 427,825 | 410,436 | ||||
| Total liabilities and equity | $ | 711,102 | $ | 681,715 | ||
| Statement of Operations Information (Unaudited) | |||||||||||||
| For the Three-Month Periods Ended June 30, | For the Six-Month Periods Ended June 30, | ||||||||||||
| 2016 | 2015 | 2016 | 2015 | ||||||||||
| Net service revenue | $ | 360,746 | $ | 314,152 | $ | 709,563 | $ | 615,724 | |||||
| Cost of service, excluding depreciation and amortization | 206,505 | 175,699 | 408,342 | 346,660 | |||||||||
| General and administrative expenses: | |||||||||||||
| Salaries and benefits | 77,343 | 71,249 | 154,060 | 139,804 | |||||||||
| Non-cash compensation | 3,736 | 2,193 | 7,806 | 4,577 | |||||||||
| Other | 45,576 | 42,113 | 92,293 | 75,183 | |||||||||
| Provision for doubtful accounts | 4,253 | 2,756 | 8,193 | 5,732 | |||||||||
| Depreciation and amortization | 4,975 | 4,615 | 9,448 | 11,152 | |||||||||
| Asset impairment charge | — | — | — | 75,193 | |||||||||
| Operating expenses | 342,388 | 298,625 | 680,142 | 658,301 | |||||||||
| Operating income (loss) | 18,358 | 15,527 | 29,421 | (42,577 | ) | ||||||||
| Other (expense) income: | |||||||||||||
| Interest income | 9 | 4 | 31 | 26 | |||||||||
| Interest expense | (1,303 | ) | (2,416 | ) | (2,415 | ) | (4,842 | ) | |||||
| Equity in earnings from equity method investments | 363 | 4,826 | 358 | 6,777 | |||||||||
| Miscellaneous, net | 658 | 498 | 1,393 | 2,632 | |||||||||
| Total other (expense) income, net | (273 | ) | 2,912 | (633 | ) | 4,593 | |||||||
| Income (loss) before income taxes | 18,085 | 18,439 | 28,788 | (37,984 | ) | ||||||||
| Income tax (expense) benefit | (7,242 | ) | (7,566 | ) | (11,630 | ) | 14,025 | ||||||
| Net income (loss) | 10,843 | 10,873 | 17,158 | (23,959 | ) | ||||||||
| Net income attributable to noncontrolling interests | (147 | ) | (236 | ) | (249 | ) | (413 | ) | |||||
| Net income (loss) attributable to Amedisys, Inc. | $ | 10,696 | $ | 10,637 | $ | 16,909 | $ | (24,372 | ) | ||||
| Basic earnings per common share: | |||||||||||||
| Net income (loss) attributable to Amedisys, Inc. common stockholders | $ | 0.32 | $ | 0.32 | $ | 0.51 | $ | (0.74 | ) | ||||
| Weighted average shares outstanding | 33,197 | 33,004 | 33,059 | 32,871 | |||||||||
| Diluted earnings per common share: | |||||||||||||
| Net income (loss) attributable to Amedisys, Inc. common stockholders | $ | 0.32 | $ | 0.32 | $ | 0.50 | $ | (0.74 | ) | ||||
| Weighted average shares outstanding | 33,708 | 33,459 | 33,641 | 32,871 | |||||||||
| Cash Flow and Days Revenue Outstanding, Net Information | ||||||||||||
| For the Three-Month Periods Ended June 30, | For the Six-Month Periods Ended June 30, | |||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||
| Net cash provided by operating activities | $ | 14,651 | $ | 42,554 | $ | 26,895 | $ | 57,037 | ||||
| Net cash used in investing activities | (3,597 | ) | (9,754 | ) | (37,751 | ) | (11,822 | ) | ||||
| Net cash used in financing activities | (8,910 | ) | (2,731 | ) | (6,678 | ) | (20,046 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 2,144 | 30,069 | (17,534 | ) | 25,169 | |||||||
| Cash and cash equivalents at beginning of period | 7,824 | 3,132 | 27,502 | 8,032 | ||||||||
| Cash and cash equivalents at end of period | $ | 9,968 | $ | 33,201 | $ | 9,968 | $ | 33,201 | ||||
| Days revenue outstanding, net (1) | 37.2 | 31.0 | 37.2 | 31.0 | ||||||||
(1) Our calculation of days revenue outstanding, net at June 30, 2016 and 2015 is derived by dividing our ending patient accounts receivable (i.e., net of estimated revenue adjustments and allowance for doubtful accounts) by our average daily net patient revenue for the three-month period ended June 30, 2016 and 2015, respectively.
| Supplemental Information - Home Health | ||||||
| For the Three-Month Periods Ended June 30, | ||||||
| Financial Information (in millions): | 2016 | 2015 | ||||
| Medicare | $ | 208.4 | $ | 188.3 | ||
| Non-Medicare | 67.1 | 59.5 | ||||
| Net service revenue | 275.5 | 247.8 | ||||
| Cost of service | 160.3 | 142.3 | ||||
| Gross margin | 115.2 | 105.5 | ||||
| Other operating expenses | 77.4 | 67.1 | ||||
| Operating income | $ | 37.8 | $ | 38.4 | ||
| Key Statistical Data: | ||||||
| Medicare: | ||||||
| Same Store Volume (1): | ||||||
| Revenue | 4 | % | (1 | %) | ||
| Admissions | 4 | % | 0 | % | ||
| Recertifications | 2 | % | (6 | %) | ||
| Total (2): | ||||||
| Admissions | 48,982 | 44,188 | ||||
| Recertifications | 26,020 | 24,607 | ||||
| Completed episodes | 74,027 | 67,702 | ||||
| Visits | 1,315,417 | 1,203,648 | ||||
| Average revenue per completed episode (3) | $ | 2,850 | $ | 2,828 | ||
| Visits per completed episode (4) | 17.7 | 17.5 | ||||
| Non-Medicare: | ||||||
| Same Store Volume (1): | ||||||
| Revenue | 13 | % | 16 | % | ||
| Admissions | 2 | % | 15 | % | ||
| Recertifications | 12 | % | 8 | % | ||
| Total (2): | ||||||
| Admissions | 24,237 | 23,792 | ||||
| Recertifications | 9,640 | 8,637 | ||||
| Visits | 515,062 | 482,689 | ||||
| Total (2): | ||||||
| Cost per Visit | $ | 87.56 | $ | 84.43 | ||
| Visits | 1,830,479 | 1,686,337 | ||||
| For the Six-Month Periods Ended June 30, | ||||||
| Financial Information (in millions): | 2016 | 2015 | ||||
| Medicare | $ | 415.2 | $ | 375.5 | ||
| Non-Medicare | 133.0 | 113.7 | ||||
| Net service revenue | 548.2 | 489.2 | ||||
| Cost of service | 321.1 | 281.0 | ||||
| Gross margin | 227.1 | 208.2 | ||||
| Other operating expenses | 153.1 | 134.0 | ||||
| Operating income | $ | 74.0 | $ | 74.2 | ||
| Key Statistical Data: | ||||||
| Medicare: | ||||||
| Same Store Volume (1): | ||||||
| Revenue | 4 | % | 2 | % | ||
| Admissions | 4 | % | 1 | % | ||
| Recertifications | 3 | % | (3 | %) | ||
| Total (2): | ||||||
| Admissions | 99,400 | 89,539 | ||||
| Recertifications | 52,043 | 48,966 | ||||
| Completed episodes | 146,059 | 133,013 | ||||
| Visits | 2,626,788 | 2,371,898 | ||||
| Average revenue per completed episode (3) | $ | 2,831 | $ | 2,811 | ||
| Visits per completed episode (4) | 17.6 | 17.4 | ||||
| Non-Medicare: | ||||||
| Same Store Volume (1): | ||||||
| Revenue | 17 | % | 18 | % | ||
| Admissions | 6 | % | 16 | % | ||
| Recertifications | 17 | % | 12 | % | ||
| Total (2): | ||||||
| Admissions | 49,804 | 46,941 | ||||
| Recertifications | 19,466 | 16,625 | ||||
| Visits | 1,043,031 | 920,154 | ||||
| Total (2): | ||||||
| Cost per Visit | $ | 87.51 | $ | 85.36 | ||
| Visits | 3,669,819 | 3,292,052 | ||||
(1) Same store Medicare and Non-Medicare revenue, admissions or recertifications growth (decline) is the percent increase (decrease) in our Medicare and Non-Medicare revenue, admissions or recertifications for the period as a percent of the Medicare and Non-Medicare revenue, admissions or recertifications of the prior period.
(2) Total includes acquisitions.
(3) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care which includes the impact of sequestration.
(4) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
| Supplemental Information - Hospice | ||||||
| For the Three-Month Periods Ended June 30, | ||||||
| 2016 | 2015 | |||||
| Medicare | $ | 71.3 | $ | 62.5 | ||
| Non-Medicare | 4.5 | 3.8 | ||||
| Net service revenue | 75.8 | 66.3 | ||||
| Cost of service | 39.4 | 33.4 | ||||
| Gross margin | 36.4 | 32.9 | ||||
| Other operating expenses | 18.4 | 16.0 | ||||
| Operating income | $ | 18.0 | $ | 16.9 | ||
| Key Statistical Data: | ||||||
| Same Store Volume (1): | ||||||
| Medicare revenue | 14 | % | 10 | % | ||
| Non-Medicare revenue | 15 | % | 5 | % | ||
| Hospice admissions | 18 | % | 11 | % | ||
| Average daily census | 16 | % | 7 | % | ||
| Total (2): | ||||||
| Hospice admissions | 5,576 | 4,713 | ||||
| Average daily census | 5,730 | 4,944 | ||||
| Revenue per day, net | $ | 145.40 | $ | 147.53 | ||
| Cost of service per day | $ | 75.69 | $ | 74.07 | ||
| Average length of stay | 94 | 86 | ||||
| For the Six-Month Periods Ended June 30, | ||||||
| 2016 | 2015 | |||||
| Financial Information (in millions): | ||||||
| Medicare | $ | 140.0 | $ | 118.9 | ||
| Non-Medicare | 8.8 | 7.6 | ||||
| Net service revenue | 148.8 | 126.5 | ||||
| Cost of service | 78.2 | 65.7 | ||||
| Gross margin | 70.6 | 60.8 | ||||
| Other operating expenses | 36.3 | 31.2 | ||||
| Operating income | $ | 34.3 | $ | 29.6 | ||
| Key Statistical Data: | ||||||
| Same Store Volume (1): | ||||||
| Medicare revenue | 18 | % | 6 | % | ||
| Non-Medicare revenue | 15 | % | 9 | % | ||
| Hospice admissions | 19 | % | 9 | % | ||
| Average daily census | 19 | % | 4 | % | ||
| Total (2): | ||||||
| Hospice admissions | 11,006 | 9,277 | ||||
| Average daily census | 5,618 | 4,744 | ||||
| Revenue per day, net | $ | 145.52 | $ | 147.39 | ||
| Cost of service per day | $ | 76.51 | $ | 76.47 | ||
| Average length of stay | 95 | 88 | ||||
(1) Same store Medicare and Non-Medicare revenue, Hospice admissions or average daily census growth (decline) is the percent increase (decrease) in our Medicare and Non-Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare and Non-Medicare revenue, Hospice admissions or average daily census of the prior period.
(2) Total includes acquisitions.
| Supplemental Information - Corporate | ||||||||||||
| For the Three-Month Periods Ended June 30, | ||||||||||||
| 2016 | 2015 | |||||||||||
| Other operating expenses | $ | 34.7 | $ | 36.8 | ||||||||
| Depreciation and amortization | 3.1 | 3.0 | ||||||||||
| Total | $ | 37.8 | $ | 39.8 | ||||||||
| For the Six-Month Periods Ended June 30, | ||||
| 2016 | 2015 | |||
| Financial Information (in millions): | ||||
| Other operating expenses | $ | 73.7 | $ | 63.6 |
| Depreciation and amortization | 6.0 | 7.6 | ||
| Total before impairment (1) | $ | 79.7 | $ | 71.2 |
1) Total of $146.4 million on a GAAP basis for the six-month period ended June 30, 2015 (including $75.2 million asset impairment charge).
AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP FINANCIAL STATEMENTS
(Amounts in thousands)
(Unaudited)
Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA:
| For the Three-Month Periods Ended June 30, | For the Six-Month Periods Ended June 30, | |||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||
| Net income (loss) attributable to Amedisys, Inc. | $ | 10,696 | $ | 10,637 | $ | 16,909 | $ | (24,372 | ) | |||
| Add: | ||||||||||||
| Income tax expense (benefit) | 7,242 | 7,566 | 11,630 | (14,025 | ) | |||||||
| Interest expense, net | 1,294 | 2,412 | 2,384 | 4,816 | ||||||||
| Depreciation and amortization | 4,975 | 4,615 | 9,448 | 11,152 | ||||||||
| EBITDA (1)(7) | 24,207 | 25,230 | 40,371 | (22,429 | ) | |||||||
| Add: | ||||||||||||
| Certain items (2) | 5,636 | 6,427 | 13,402 | 80,467 | ||||||||
| Adjusted EBITDA (3)(7) | $ | 29,843 | $ | 31,657 | $ | 53,773 | $ | 58,038 | ||||
Adjusted Net Service Revenue Reconciliation:
| For the Three-Month Periods Ended June 30, | For the Six-Month Periods Ended June 30, | |||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||
| Net service revenue | $ | 360,746 | $ | 314,152 | $ | 709,563 | $ | 615,724 | ||||
| Add: | ||||||||||||
| Certain items (2) | 948 | — | 948 | — | ||||||||
| Adjusted net service revenue (4)(7) | $ | 361,694 | $ | 314,152 | $ | 710,511 | $ | 615,724 | ||||
Adjusted Net Income Attributable to Amedisys, Inc. Reconciliation:
| For the Three-Month Periods Ended June 30, | For the Six-Month Periods Ended June 30, | |||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||
| Net income (loss) attributable to Amedisys, Inc. | $ | 10,696 | $ | 10,637 | $ | 16,909 | $ | (24,372 | ) | |||
| Add: | ||||||||||||
| Certain items (2) | 3,410 | 3,888 | 8,108 | 48,682 | ||||||||
| Adjusted net income attributable to Amedisys, Inc. (5)(7) | $ | 14,106 | $ | 14,525 | $ | 25,017 | $ | 24,310 | ||||
Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share:
| For the Three-Month Periods Ended June 30, | For the Six-Month Periods Ended June 30, | |||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||
| Net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share | $ | 0.32 | $ | 0.32 | $ | 0.50 | $ | (0.74 | ) | |||
| Add: | ||||||||||||
| Certain items (2) | 0.10 | 0.12 | 0.24 | 1.48 | ||||||||
| Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (6)(7) | $ | 0.42 | $ | 0.43 | $ | 0.74 | $ | 0.73 | ||||
(1) EBITDA is defined as net income (loss) attributable to Amedisys, Inc. before provision for income taxes, net interest expense, and depreciation and amortization.
(2) The following details the certain items for the three and six-month periods ended June 30, 2016 and 2015:
| For the Three-Month Period Ended June 30, 2016 | For the Six-Month Period Ended June 30, 2016 | |||||
| (Income) Expense | (Income) Expense | |||||
| HCHB implementation | $ | 2,593 | $ | 5,033 | ||
| Acquisition costs | 337 | 2,042 | ||||
| Legal fees - non-routine | 459 | 1,976 | ||||
| Legal settlements | (265 | ) | (806 | ) | ||
| Restructuring activity | 1,494 | 3,703 | ||||
| Third party audit reserve | 948 | 948 | ||||
| Miscellaneous, other (income) expense, net | 70 | 506 | ||||
| Total | $ | 5,636 | $ | 13,402 | ||
| Net of tax | 3,410 | 8,108 | ||||
| Diluted EPS | 0.10 | 0.24 | ||||
| For the Three-Month Period Ended June 30, 2015 | For the Six-Month Period Ended June 30, 2015 | |||||
| (Income) Expense | (Income) Expense | |||||
| Wage and Hour litigation | $ | 8,000 | $ | 8,000 | ||
| Legal settlements | (307 | ) | (1,125 | ) | ||
| Inventory and Data Security Reporting | — | 2,121 | ||||
| Asset impairment | — | 75,193 | ||||
| Restructuring activity | 2,679 | 2,679 | ||||
| Miscellaneous, other (income) expense, net | (3,945 | ) | (6,401 | ) | ||
| Total | $ | 6,427 | $ | 80,467 | ||
| Net of tax | $ | 3,888 | $ | 48,682 | ||
| Diluted EPS | $ | 0.12 | $ | 1.48 | ||
(3) Adjusted EBITDA is defined as EBITDA, as defined in footnote 1, excluding certain items as described in footnote 2.
(4) Adjusted net service revenue is defined as net service revenue plus certain items as described in footnote 2.
(5) Adjusted net income attributable to Amedisys, Inc. is defined as net income (loss) attributable to Amedisys, Inc. excluding certain other items as described in footnote 2.
(6) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income (loss) per share excluding the earnings per share effect of certain items as described in footnote 2.
(7) EBITDA, adjusted EBITDA, adjusted net service revenue, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.